New Stock News | Frontera Therapeutics Submits Application to Hong Kong Stock Exchange

According to the disclosure by Hong Kong Stock Exchange on December 23, Frontera Therapeutics has submitted its application for listing on the main board of the Hong Kong Stock Exchange, with UBS Securities Hong Kong Limited and Haitong Int'l Capital Limited as its joint sponsors. According to the prospectus, Frontera Therapeutics is a clinical-stage gene therapy company focusing on the development of innovative therapies, with an international business layout, dedicated to providing safe, effective, and affordable gene therapy solutions for patients worldwide. Since its establishment in 2019, the company has been dedicated to the independent development of innovative recombinant adeno-associated virus ("rAAV") gene therapy. The company has developed a differentiated and clinically advanced pipeline with the best global potential in its class, particularly targeting ophthalmology and cardiovascular diseases.